文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

低强度与标准强度华法林预防对髋或膝关节置换术患者静脉血栓栓塞或死亡的影响:一项随机临床试验

Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

在6个美国医学中心纳入1650例65岁及以上择期髋或膝关节置换术患者,随机分配至目标INR 1.8或2.5。主要复合终点(60天内VTE或30天内死亡)发生率低强度组5.1% vs 标准强度组3.8%,差异1.3%(单侧95%CI -∞至3.05%,非劣效性P=0.06),未达到非劣效性标准。

要点

  • 低强度华法林(目标INR 1.8)相比标准强度(目标INR 2.5)未达到预设的非劣效性标准。
  • 低强度组主要复合终点5.1% vs 标准组3.8%,差异1.3%(单侧95%CI -∞至3.05%,非劣效性P=0.06)。
  • INR≥4的发生率低强度组4.5% vs 标准组12.2%,差异-7.8%(95%CI -10.5%至-5.1%)。

核心结论

  • 在接受华法林预防的老年髋或膝关节置换术患者中,目标INR 1.8相比2.5未达到静脉血栓栓塞或死亡复合结局风险的非劣效性标准。
  • 该试验可能把握度不足,需进一步研究。

研究设计与样本

  • 随机遗传信息学试验(GIFT),2×2析因设计,纳入1650例65岁及以上择期髋或膝关节置换术患者。
  • 6个美国医学中心参与,2011年4月开始入组,2016年10月完成随访。
  • 参与者随机分配至目标INR 1.8(n=823)或2.5(n=827),同时随机分配至基因指导或临床指导华法林给药。
  • 治疗前11天,开放标签华法林给药由网络应用程序指导。
  • 1650例随机患者中1597例(96.8%)至少接受1剂华法林并纳入主要分析。

主要发现

  • 主要复合结局(60天内VTE或30天内死亡)发生率:低强度组5.1%(804例中41例)vs 标准强度组3.8%(793例中30例),差异1.3%(单侧95%CI -∞至3.05%,非劣效性P=0.06)。
  • 大出血发生率:低强度组0.4% vs 标准强度组0.9%,差异-0.5%(95%CI -1.6%至0.4%)。
  • INR≥4发生率:低强度组4.5% vs 标准强度组12.2%,差异-7.8%(95%CI -10.5%至-5.1%)。
  • 随机患者平均年龄72.1岁,女性1049例(63.6%),白人1502例(91.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该试验可能把握度不足以达到非劣效性标准。
  • 需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The optimal international normalized ratio (INR) to prevent venous thromboembolism (VTE) in warfarin-treated patients with recent arthroplasty is unknown. OBJECTIVE: To determine the safety and efficacy of a target INR of 1.8 vs 2.5 for VTE prophylaxis after orthopedic surgery. DESIGN, SETTING, AND PARTICIPANTS: The randomized Genetic Informatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis enrolled 1650 patients aged 65 years or older initiating warfarin for elective hip or knee arthroplasty at 6 US medical centers. Enrollment began in April 2011 and follow-up concluded in October 2016. INTERVENTIONS: In a 2 × 2 factorial design, participants were randomized to a target INR of 1.8 (n = 823) or 2.5 (n = 827) and to either genotype-guided or clinically guided warfarin dosing. For the first 11 days of therapy, open-label warfarin dosing was guided by a web application. MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of VTE (within 60 days) or death (within 30 days). Participants underwent screening duplex ultrasound postoperatively. The hypothesis was that an INR target of 1.8 would be noninferior to an INR target of 2.5, using a noninferiority margin of 3% for the absolute risk of VTE. Secondary end points were bleeding and INR values of 4 or more. RESULTS: Among 1650 patients who were randomized (mean age, 72.1 years; 1049 women [63.6%]; 1502 white [91.0%]), 1597 (96.8%) received at least 1 dose of warfarin and were included in the primary analysis. The rate of the primary composite outcome of VTE or death was 5.1% (41 of 804) in the low-intensity-warfarin group (INR target, 1.8) vs 3.8% (30 of 793) in the standard-treatment-warfarin group (INR target, 2.5), for a difference of 1.3% (1-sided 95% CI, -∞ to 3.05%, P = .06 for noninferiority). Major bleeding occurred in 0.4% of patients in the low-intensity group and 0.9% of patients in the standard-intensity group, for a difference of -0.5% (95% CI, -1.6% to 0.4%). The INR values of 4 or more occurred in 4.5% of patients in the low-intensity group and 12.2% of the standard-intensity group, for a difference of -7.8% (95% CI, -10.5% to -5.1%). CONCLUSIONS AND RELEVANCE: Among older patients undergoing hip or knee arthroplasty and receiving warfarin prophylaxis, an international normalized ratio goal of 1.8 compared with 2.5 did not meet the criterion for noninferiority for risk of the composite outcome of VTE or death. However, the trial may have been underpowered to meet this criterion and further research may be warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01006733.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Gage BF, Bass AR, Lin H, et al. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. JAMA. 2019. PMID: 31479138. doi:10.1001/jama.2019.12085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。